Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology
Looking for a particular Cyprotex employee's phone or email?
The Cyprotex annual revenue was $31.7 million in 2026.
Stephen Madden is the SVP Head Global Operations Cyprotex of Cyprotex.
183 people are employed at Cyprotex.
The NAICS codes for Cyprotex are [541, 54199, 5419, 54].
The SIC codes for Cyprotex are [59, 591, 873, 87].